NewLink Genetics (NASDAQ:NLNK) Upgraded to Hold at BidaskClub

BidaskClub upgraded shares of NewLink Genetics (NASDAQ:NLNK) from a sell rating to a hold rating in a report published on Friday, January 5th.

Other equities analysts have also issued research reports about the company. ValuEngine lowered NewLink Genetics from a sell rating to a strong sell rating in a research note on Tuesday, September 26th. Zacks Investment Research raised NewLink Genetics from a hold rating to a buy rating and set a $10.00 price target on the stock in a research note on Tuesday, November 7th. Jefferies Group upgraded NewLink Genetics from a hold rating to a buy rating and boosted their price objective for the company from $7.00 to $26.00 in a report on Friday, September 8th. Cantor Fitzgerald reiterated a buy rating and issued a $26.00 price objective on shares of NewLink Genetics in a report on Monday, September 25th. Finally, Stifel Nicolaus boosted their price objective on NewLink Genetics from $25.00 to $29.00 and gave the company a buy rating in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $23.29.

Shares of NewLink Genetics (NASDAQ NLNK) traded down $0.16 during trading hours on Friday, hitting $8.25. The stock had a trading volume of 553,572 shares, compared to its average volume of 777,704. The firm has a market capitalization of $298.83, a price-to-earnings ratio of -3.38 and a beta of 1.10. NewLink Genetics has a 12-month low of $5.90 and a 12-month high of $25.17.

NewLink Genetics (NASDAQ:NLNK) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.05. NewLink Genetics had a negative return on equity of 63.39% and a negative net margin of 229.19%. research analysts forecast that NewLink Genetics will post -2.65 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in NewLink Genetics by 1,823.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 9,735 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in NewLink Genetics during the 3rd quarter worth about $114,000. State of Wisconsin Investment Board purchased a new stake in NewLink Genetics during the 2nd quarter worth about $125,000. Advisor Group Inc. increased its holdings in NewLink Genetics by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 600 shares during the period. Finally, Creative Planning acquired a new position in shares of NewLink Genetics during the 4th quarter worth about $152,000. Institutional investors own 52.68% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by BBNS and is owned by of BBNS. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://baseballnewssource.com/markets/newlink-genetics-nlnk-upgraded-to-hold-at-bidaskclub/1820828.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish


Leave a Reply

 
© 2006-2018 BBNS.